11:30 AM SIGN-IN & LUNCH • 12:00 PM - 1:30 PM

BANDOL 2 (NEW WYNN SPACE)

CE: Diabetic Retinopathy and Macular Edema: Treatment and Management Updates

Diabetic retinopathy (DR) is a common microvascular complication affecting approximately 86% of patients with type 1 diabetes and 40% of patients with type 2 diabetes. Overall, nearly 25% of patients with diabetes and DR are at risk for progressing to diabetic macular edema (DME), characterized by edema and retinal thickening, and subsequent vision loss. Mitigating treatment options include nonpharmacologic therapies, such as laser photocoagulation; vitrectomy; and pharmacologic options, such as corticosteroids and vascular endothelial growth factor (VEGF) inhibitors. To improve clinical outcomes in patients with DME, pharmacists must consider severity of disease, patient compliance, and cost effectiveness of agents prior to selection of therapy. This activity will highlight several opportunities for specialty pharmacists to take active roles in counseling patients from the importance of managing their diabetes and other comorbidities contributing to DR and DME to inquiring about patients’ adherence to regularly scheduled eye exams.

Speakers

Asembia

200 Park Avenue, Suite 300 
Florham Park, NJ 07932

973.564.8004

asembia.com

info@asembiasummit.com

SIGN UP FOR SUMMIT UPDATES

Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

Terms & Conditions © 2019 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.

CONNECT WITH US

  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos
SummitLogo_2020_White.png